IL2 and breast carcinoma: ADCC with PBMCs (effector to target rate 100:1) after 4 hRCC—SK-RC-13: cG250 48%; cG250 + IL2 50%;SK-RC-30: cG250 25%; cG250 + IL2 65%;Breast cancer—BT-20: cG250 38%; cG250 + IL2 28%